Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B progran, no specific bill. Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors
Source-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- Apr 21, 2025
- Income
- Not reported
- Expenses
- $1,020,000.00
- Registrant
- BIOGEN
- Client
- BIOGEN
- Filing UUID
- 6630c7a7-9519-4654-a2f5-a9e4d2c2dd28
- Termination date
- Not reported
Expense method: A
Literal source text
Lobbying issues and bill citations
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
General issues related to the manufacturing workforce
Trade-related public policy around tariffs and intellectual property, no related bills
Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Support stronger IP and exclusivity protections and enforcement in foreign markets Biopharmaceutical innovation and patent policy Bayh-Dole March-in rights, Patent thicket, and AI policy issues
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.